In situ misemgel as a multifunctional dual-absorption platform for nasal delivery of raloxifene hydrochloride: formulation, characterization, and in vivo performance

BACKGROUND: Raloxifene hydrochloride (RLX) is approved by the US Food and Drug Administration for the treatment and prevention of osteoporosis, in addition to reducing the risk of breast cancer in postmenopausal women. RLX has the disadvantages of low aqueous solubility, extensive presystemic intest...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, Osama AA, Badr-Eldin, Shaimaa M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188068/
https://www.ncbi.nlm.nih.gov/pubmed/30349253
http://dx.doi.org/10.2147/IJN.S181587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188068/
https://www.ncbi.nlm.nih.gov/pubmed/30349253
http://dx.doi.org/10.2147/IJN.S181587

Ejemplares similares